ClinicalTrials.gg
CompletedNCT05901649ArtemisPROUpdated Jul 31, 2026

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

An observational study in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Janssen-Cilag Ltd.. Completed at 53 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
505
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.

Enrollment
6th of 16
505 · median 300
Started
2023
with 3 others
Observational
16 of 88
1 open now
Registered
80th of 88
by date

Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 6th largest by enrollment of the 16 observational ones that give a count, is one of 4 that started in 2023, is one of 16 observational ones, and was the 80th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Prostatic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC).

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who will be treated with either apalutamide or enzalutamide plus androgen deprivation therapy (ADT) under routine clinical practice will be observed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a or cytologically-confirmed diagnosis of adenocarcinoma of the prostate
  • Must have documented hormone-sensitive prostate cancer (mHSPC)
  • Must have agreed with the treating physician the initiation of either apalutamide or enzalutamide (plus androgen deprivation therapy [ADT]) treatment, per the treating physician's decision, prior to enrollment into the study
  • Must sign, and/or their legally acceptable representative where applicable must sign, a participation agreement/ form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Must have baseline prostate-specific antigen (PSA) captured within 30 days prior to the first administration of apalutamide or enzalutamide
  • Must agree to complete patient-reported outcomes (PROs) during the study, including the baseline ones collected before the first administration of apalutamide or enzalutamide

Exclusion criteria

Exclusion Criteria:

  • Has already received or is currently receiving either apalutamide or enzalutamide, or any other novel hormonal treatments (including but not limited to abiraterone acetate and darolutamide)
  • Is currently receiving an active treatment for prostate cancer as part of an interventional study
  • Has a progression under ADT treatment (and thus became castrate-resistant) prior to start of apalutamide or enzalutamide treatment
  • Has received ADT treatment for mHSPC for more than 2 months prior to apalutamide or enzalutamide treatment initiation or ADT treatment was administered for earlier disease stages within the last 12 months prior to apalutamide or enzalutamide treatment initiation
  • Has received prior docetaxel for the treatment of mHSPC
  • Participants is not treated in line with current Summary of Product Characteristics for apalutamide or enzalutamide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
505 participants (actual)
Patient registry
No

Groups and cohorts

  • Apalutamide Plus Androgen Deprivation Therapy (ADT)

    Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with apalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.

    Drug: Apalutamide

  • Enzalutamide Plus Androgen Deprivation Therapy (ADT)

    Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with enzalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.

    Drug: Enzalutamide

Interventions

  • No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.

    Also known as: ERLEADA

  • No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.

    Also known as: XTANDI

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Prostate-specific Antigen (PSA) Level <0.2 ng/mL at Month 3

    Percentage of participants with PSA level less than (\<)0.2 nanogram per milliliter (ng/mL) at month 3 will be reported.

    Time frame: At month 3

  2. Health-Related Quality of Life (HRQoL) as Assessed by Partial European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Questionnaire

    HRQoL of the participants will be assessed as partial EORTC QLQ-C30 questionnaire. EORTC QLQ-C30 scale scores range from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom.

    Time frame: Up to 30 Months

  3. Cognitive Functioning as Assessed by Partial Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) Questionnaire

    Cognitive function of the participants will be measured by the partial FACT-Cog (Version 3) questionnaire. The FACT-Cog score ranges from scale 0-148. The higher the total score, the better the cognitive function.

    Time frame: Up to 30 Months

  4. Fatigue as Assessed by Brief Fatigue Inventory-Short Form (BFI-SF) Questionnaire

    Participant fatigue will be assessed by the BFI-SF questionnaire. The BFI-SF score range from scale 0-10. Scores are categorized as Mild (1-3), Moderate (4-6), and Severe (7-10).

    Time frame: Up to 30 Months

  5. Prostate-specific Antigen (PSA) Anxiety as Assessed by Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Questionnaire

    PSA anxiety of the participant will be assessed by the MAX-PC questionnaire. The MAX-PC total score ranges from scale 0 to 54. The MAX-PC is divided into three subscales: a) prostate cancer anxiety (PCA) range from 0 to 33, b) Prostate-Specific Antigen Anxiety (PSAA) ranges from 0 to 9, and c) fear of recurrence (FOR) ranges from 0 to 12.

    Time frame: Up to 30 Months

07

Study locations

53 sites
  • Akh Wien
    Vienna, 1090, Austria
  • Klinikum Wels Grieskirchen
    Wels, 4600, Austria
  • Institut Sainte Catherine
    Avignon, 84918, France
  • Institut Bergonie
    Bordeaux, 33000, France
  • Polyclinique Bordeaux Nord Acquitaine
    Bordeaux, 33077, France
  • Clinique Pasteur- Lanroze
    Brest, 29229, France
  • Hopital Michallon CHU Grenoble Alpes
    La Tronche, 38700, France
  • Hôpital Edouard Herriot
    Lyon, 69003, France
  • Centre d'oncologie de Gentilly
    Nancy, 54100, France
  • CHU Nimes
    Nîmes, 30029, France
  • Hopital Europeen Georges-Pompidou
    Paris, 75015, France
  • Hopital Tenon
    Paris, 75020, France
  • Centre Hospitalier Rene Dubos Pontoise
    Pontoise, 95303, France
  • Clinique de la Croix du Sud
    Quint-Fonsegrives, 31130, France
  • Centre Hospitalier Prive
    Saint-Grégoire, 35760, France
  • Clinique Sainte Anne
    Strasbourg, 67000, France
  • Hopital Foch
    Suresnes, 92150, France
  • CHU de Toulouse
    Toulouse, 31059, France
  • Urologie Dierdorf
    Dierdorf, 56269, Germany
  • St. Elisabeth Hospital Leipzig
    Dresden, 01307, Germany
  • Urologicum Duisburg
    Duisburg, 47169, Germany
  • Urologisches Zentrum Mittelhessen
    Gladenbach, 35075, Germany
  • Praxis Dr. Serkan Filiz
    Hamburg, 22880, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, 55131, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Krankenhaus Barmherzige Brüder Regensburg
    Regensburg, 93049, Germany
  • Alexandra General Hospital of Athens
    Athens, 115 28, Greece
  • Anticancer Oncology Hospital of Athens Agios Savvas
    Athens, 11522, Greece
  • Attikon University General Hospital of Attica
    Athens, 12462, Greece
  • General Oncology Hospital of Kifisias "Agioi Anargyroi
    Athens, 14564, Greece
  • University Hospital of Heraklion
    Heraklion, 71110, Greece
  • University General Hospital of Rio Patras
    Pátrai, 26504, Greece
  • Papageorgiou General Hospital Of Thessaloniki
    Thessaloniki, TK 56403, Greece
  • Hosp Univ A Coruna
    A Coruña, 15006, Spain
  • Hosp. Torrecardenas
    Almería, 04009, Spain
  • Hosp. Puerta Del Mar
    Cadiz, 11009, Spain
  • Hosp. Gral. Univ. de Castellon
    Castellon, 12004, Spain
  • Hosp. Univ. Lucus Augusti
    Lugo, 27003, Spain
  • Hosp Regional Univ de Malaga
    Málaga, 29010, Spain
  • Hosp. Univ. de Canarias
    San Cristóbal de La Laguna, 38320, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Lewisham & Greenwich NHS Trust
    Berkshire, SL2 4HL, United Kingdom
  • Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
    Cornwall, TR1 3LJ, United Kingdom
  • Torbay Hospital-Devon
    Devon, TQ2 7AA, United Kingdom
  • Dorset County Hospital Nhs Foundation Trust
    Dorchester, DT1 2JY, United Kingdom
  • Royal Surrey County Hospital NHS Trust
    Guildford, GU2 7XX, United Kingdom
  • University College London Hospitals Nhs Foundation Trust
    London, NW1 2PG, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • Northern Care Alliance NHS Foundation Trust
    Oldham, OL1 2JH, United Kingdom
  • Northern Lincolnshire and Goole NHS Foundation Trust
    Scunthorpe, DN15 7BH, United Kingdom
  • Taunton and Somerset NHS Foundation Trust
    Taunton, TA1 5DA, United Kingdom
  • University Hospitals Sussex NHS Foundation Trust Worthing Hospital
    Worthing, BN11 2DH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2026, 35 months.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's 35 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 13, 2023
StartActual
Jul 5, 2023
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05901649
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Jul 5, 2023
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Jul 31, 2026

Study contacts

Janssen-Cilag Ltd Clinical Trial
study director · Janssen-Cilag Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion